Keyphrases
Phase I Study
100%
Interleukin-2
100%
Patients with Advanced Cancer
100%
Interferon alpha-2b
100%
Renal Cell Carcinoma
40%
Maximum Tolerated
40%
Tumor
20%
Serum Levels
20%
Flow Cytometry
20%
Dose-limiting Toxicity
20%
Dose Level
20%
Hypotension
20%
Previously Untreated
20%
Natural Killer Cell Activity
20%
Histology
20%
Partial Response
20%
Creatinine
20%
Immunological Surveillance
20%
Soluble interleukin-2 Receptor (sIL-2R)
20%
Prognostic Features
20%
Toxicity Response
20%
First Treatment
20%
Melanoma Patients
20%
Cytokine Therapy
20%
Objective Response
20%
High-dose interleukin-2
20%
Metastatic Renal Cell Carcinoma (mRCC)
20%
Neopterin
20%
Durable Remission
20%
Pharmacology, Toxicology and Pharmaceutical Science
Advanced Cancer
100%
Interleukin 2
100%
Alpha2a Interferon
100%
Maximum Tolerated Dose
33%
Renal Cell Carcinoma
33%
Neoplasm
16%
Creatinine
16%
Cytokine
16%
Symptom
16%
Flow Cytometry
16%
Hypotension
16%
Melanoma
16%
Remission
16%
Kidney Metastasis
16%
Soluble Interleukin 2 Receptor
16%
Neopterin
16%